No Detail Found!

Efficacy and side effects of hydroxyurea in patient with thalassemia intermedia

Author(s)
Fouzia Ishaq Sir Ganga Ram Hospital, Lahore, PAKISTAN
Jovaria Mannan Sir Ganga Ram Hospital, Lahore, PAKISTAN
Talat Seyal Sir Ganga Ram Hospital, Lahore, PAKISTAN
Hasnain Abid Sir Ganga Ram Hospital, Lahore, PAKISTAN
Sadia Hassan. Sir Ganga Ram Hospital, Lahore, PAKISTAN
Abstract
Objective: Purpose of this study was to determine the efficacy and possible side effects of Hydroxyurea (HU) in patient with Thalassemia Intermedia and its relation to I-globin gene mutations. Study Design: Non Randomized Experimental Study. Study Place & Duration: The study was undertaken at Thalassemia Center, Sir Ganga Ram Hospital Lahore over 3 years period from February, 2007 Jan, 2010. Patients & Methods: Fifty five patients of thalassemia Intermedia with mean age of 8.6 years, comprising of 28 males and 27 females were given Hydroxyurea in a single daily dose of 15 mg/kg orally with oral folic acid. Twenty nine (53%) were blood transfusion dependent, seventeen (31%) had received 1-2 blood transfusion and nine (16%) were never transfused prior to starting HU. Response of drug was evaluated in terms of rise in hemoglobin (g/dl) or  a reduction in transfusion requirement. Median follow up of patients was 12 months (range 6 -36 months). Response criterion was classified into good, partial and no response as below: Good Response: Transfusion Independence or Hb rise of > 2g/dl. Partial Response:Rise in Hb of 1-2 g/dl or reduction in transfusion frequency by 50%. No Response: No rise in Hb or remained at the same level of transfusion dependency. Blood samples were also examined by Amplification Refractory Mutation Specific (ARMS) PCR for common beta-thalassemia mutations and results were correlated with response to HU. Mutations in eighteen patients could not be studied due to economic constraint. Results: In our study 80% patients showed response to HU. Thirty eight (69%) were good responders and six (11%) showed partial response. Among good responders, 66% had a rise in hemoglobin > 2 g/dl and reduction in spleen size was found in 60.7%. All 38 patients became transfusion independent (100%). Only 2 (3.6%) patients complained at nausea, mild abdominal pain and diarrhea. On analysis of beta globin gene mutations in 37 TI patients, five common mutations identified were IVS1-5, CD-30, Codon 8/9 (+G), Fr 8-9 (+G) and CD 41/42 these constituted 86.4% of total mutations. In our study three patients with good response and one patient with partial response had Codon 8/9 (+G) mutation, but none of seven non-responder patients had this mutation. Conclusion: Hydroxyurea is a safe, well tolerated and affordable drug with minimal side effects for patients with β thalassemia intermedia. Patients clinically diagnosed as TI and receiving regular blood transfusions can also be given a trial of HU to minimize or even eliminate the need for regular blood transfusion and concomitant iron over load.
Publication Details
Page(s) 8-12
DOI DOI not available
Published Journal: Pakistan Paediatric Journal, Volume: 35, Issue: 1, Year: 2011

Request the full text from PASTIC

0

Citations

0

Downloads

117

Views